Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$6.71 - $11.83 $1,006 - $1,774
150 Added 85.71%
325 $2,000
Q2 2023

Aug 14, 2023

SELL
$11.12 - $22.2 $4,726 - $9,435
-425 Reduced 70.83%
175 $2,000
Q1 2023

May 11, 2023

BUY
$18.7 - $23.07 $11,220 - $13,842
600 New
600 $12,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $270M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Colonial Trust CO / Sc Portfolio

Follow Colonial Trust CO / Sc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Colonial Trust CO / Sc, based on Form 13F filings with the SEC.

News

Stay updated on Colonial Trust CO / Sc with notifications on news.